Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels by controlling ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Register for Details

For more details on financing and valuation for Nurix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Nurix's ticker symbol?


What is Nurix's stock price?

7.23 as of 10/2/23

Learn more about Nurix

Forge green plus iconForge green minus icon

What is Nurix funding to date?

Nurix has raised $48.38MM to date.
Forge green plus iconForge green minus icon

When was Nurix founded?

Nurix was founded in 2012.
Updated on: Jun 12, 2022


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.